During the past decade, Osaka International Cancer Institute conducted 108 clinical trials. In the 10-year time frame, 108 clinical trials started and 31 clinical trials were completed, i.e. on average, 28.7% percent of trials that started reached the finish line to date. In the past 5 years, 60 clinical trials started and 25 clinical trials were completed. i.e. 41.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Osaka International Cancer Institute" #1 sponsor was "Hoffmann-La Roche" with 23 trials, followed by "Pfizer" with 10 trials sponsored, "Incyte Corporation" with 7 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "Daiichi Sankyo, Inc." with 6 trials sponsored. Other sponsors include 56 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Osaka International Cancer Institute" #1 collaborator was "AstraZeneca" with 6 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator and "Breast International Group" with 2 trials as a collaborator. Other collaborators include 45 different institutions and companies that were collaborators in the rest 51 trials.

According to Clinical.Site data, the most researched conditions in "Osaka International Cancer Institute" are "Breast Cancer" (6 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials), "Non-Small Cell Lung Cancer" (5 trials), "Gastric Cancer" (3 trials) and "Metastatic Breast Cancer" (3 trials). Many other conditions were trialed in "Osaka International Cancer Institute" in a lesser frequency.

Most popular intervention types in "Osaka International Cancer Institute" are "Drug" (109 trials), "Other" (5 trials), "Biological" (4 trials), "Radiation" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Paclitaxel" (14 trials), "Carboplatin" (12 trials), "Cisplatin" (11 trials) and "Atezolizumab" (10 trials). Other intervention names were less common.

The vast majority of trials in "Osaka International Cancer Institute" are 101 trials for "All" genders, 8 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Osaka International Cancer Institute". 1 are not yet recruiting, 34 are recruiting, 41 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Osaka International Cancer Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Osaka International Cancer Institute, 17 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 74 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".